Cambridge-founded chemicals products maker Aqdot has welcomed the return of IP Group and Parkwalk Advisors in its latest round, taking its funding total to $16.5m.

Novo and Sanofi Ventures returned to reinvest in Yale spinout Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.

UTokyo's Innovation Platform joined subsidiaries of SBI, Sumitomo Mitsui and Mizuho Bank to help double genetic disorder treatment developer EdiGene's funding.

Cancer drug developer NH Theraguix was incubated by Satt Pulsalys to advance a nanoparticle-based drug for solid tumours that works by enhancing the efficacy of radiotherapy treatment and MRI scans.

Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.

Sabic has equipped Mallinda with funding as the CU Boulder-founded thermoset resins provider gears up for the launch of its first commercial product.

Vector has received funding from UC-backed Congruent Ventures among others as it looks to enhance its software in supporting back office logistics functions.

NUI Maynooth spinout Avectas has added capital to converted equity previously supplied by therapeutics developer Adapt Pharma among others.

UVA’s seed fund and corporate venturing unit PharmStandard Ventures featured in topical dry eye syndrome peptide spinout TearSolutions' financing round, taking its total to $21.5m.

NovaUCD-based patient lingerie manufacturer Theya Healthcare has been backed by investors including Enterprise Ireland as it prepares for expansion in the US.